Financials data is unavailable for this security.
View more
Year on year ScinoPharm Taiwan Ltd 's net income fell -18.73% from 353.22m to 287.06m despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 61.68% to 61.83%.
| Gross margin | 38.89% |
|---|---|
| Net profit margin | 11.76% |
| Operating margin | 12.89% |
| Return on assets | 3.37% |
|---|---|
| Return on equity | 3.92% |
| Return on investment | 3.69% |
More ▼
Cash flow in TWDView more
In 2023, cash reserves at ScinoPharm Taiwan Ltd fell by 353.19m. However, the company earned 231.13m from its operations for a Cash Flow Margin of 7.25%. In addition the company used 233.29m on investing activities and also paid 340.98m in financing cash flows.
| Cash flow per share | 1.10 |
|---|---|
| Price/Cash flow per share | 22.74 |
| Book value per share | 13.12 |
|---|---|
| Tangible book value per share | 13.09 |
More ▼
Balance sheet in TWDView more
| Current ratio | 6.86 |
|---|---|
| Quick ratio | 5.00 |
| Total debt/total equity | 0.0629 |
|---|---|
| Total debt/total capital | 0.0592 |
More ▼
Growth rates in TWD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -16.67% and -18.70%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.
| Div yield(5 year avg) | 1.45% |
|---|---|
| Div growth rate (5 year) | -9.35% |
| Payout ratio (TTM) | 58.86% |
| EPS growth(5 years) | -8.29 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 54.23 |
More ▼
